Expression of Rab1A in bladder cancer and its clinical implications

Su,Hongwei; Li,Ting; Li,Chen; Liu,Xin; Ling,Haibin; Li,Xiangdong

doi:10.3892/etm.2020.9174

Expression of Rab1A in bladder cancer and its clinical implications

Authors:
- Hongwei Su
- Ting Li
- Chen Li
- Xin Liu
- Haibin Ling
- Xiangdong Li
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075061, P.R. China, Department of Drug and Equipment, The Second Hospital of Zhangjiakou City, Zhangjiakou, Hebei 075061, P.R. China
Published online on: September 3, 2020 https://doi.org/10.3892/etm.2020.9174
Article Number: 44
Copyright: © Su et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rab1A protein has been identified to be highly expressed in a number of malignant tumor tissues and to participate in the regulation of tumor development, but no data concerning bladder cancer have been described at present. The present study measured the expression of Rab1A in bladder cancer tissues and cell lines, and analyzed its clinical significance for patients with bladder cancer. A total of 153 pairs of bladder cancer tumor tissues and adjacent cancer healthy tissues were included in the present study. Western blot analysis and immunohistochemistry were used to measure the expression of Rab1A protein in normal bladder and bladder cancer cell line, and bladder cancer and normal adjacent tissues. SPSS 20.0 software was used for statistical analysis and mapping of survival curves in patients with bladder cancer. The expression levels of Rab1A protein in normal bladder cells and tissues was significantly decreased compared with that in bladder cancer cells and tissues, and it was significantly associated with tumor size, histological grade, tumor‑node‑metastasis (TNM) stage, lymph node metastasis and remote metastasis in 153 patients with bladder cancer. Cox regression analysis demonstrated that the expression of Rab1A protein in bladder cancer tissues was an independent risk factor for prognosis (overall risk=0.549; 95% confidence interval=0.139‑0.916). The 5‑year survival rate of patients with bladder cancer with high expression levels of Rab1A protein was 48.613%, which was significantly decreased compared with the rate of patients with low expression 75.31% (P<0.05). The expression of Rab1A in bladder cancer tissues and cell lines was upregulated, and its expression increased with increasing TNM stages. It was also associated with the metastasis of tumor cells and negatively affected the survival time of patients with bladder cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. Ca Cancer J Clin. 62:10–29. 2012.PubMed/NCBI View Article : Google Scholar
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
3	Wei F, Wu Y, Tang L, Xiong F, Guo C, Li X, Zhou M, Xiang B, Li X, Li G, et al: Trend analysis of cancer incidence and mortality in China. Sci China Life Sci. 60:1271–1275. 2017.PubMed/NCBI View Article : Google Scholar
4	Quan Y, Song Q, Wang J, Zhao L, Lv J and Gong S: MiR-1202 functions as a tumor suppressor in glioma cells by targeting Rab1A. Tumor Biol. 39(101042831769756)2017.PubMed/NCBI View Article : Google Scholar
5	Allan BB, Moyer BD and Balch WE: Rab1 recruitment of p115 into a cis-SNARE complex: Programming budding COPII vesicles for fusion. Science. 289:444–448. 2000.PubMed/NCBI View Article : Google Scholar
6	Satoh A, Wang Y, Malsam J, Beard MB and Warren G: Golgin-84 is a rab1 binding partner involved in golgi structure. Traffic. 4:153–161. 2010.
7	Thomas JD, Zhang YJ, Wei YH, Cho JH, Morris LE, Wang HY and Zheng XF: Rab1A is an mTORC1 activator and a colorectal oncogene. Cancer Cell. 26:754–769. 2014.PubMed/NCBI View Article : Google Scholar
8	Xu BH, Li XX, Wang HY and Zheng XS: Overexpressed Rab1A is associated poor prognosis and promotes oncogenic growth and metastasis through mTORC1 activation in hepatocellular carcinoma. AACR, 2015.
9	Mukhopadhyay A, Nieves E, Che FY, Wang J, Jin L, Murray JW, Gordon K, Angeletti RH and Wolkoff AW: Proteomic analysis of endocytic vesicles: Rab1a regulates motility of early endocytic vesicles. J Cell Sci. 124:765–775. 2011.PubMed/NCBI View Article : Google Scholar
10	Mukhopadhyay A, Quiroz JA and Wolkoff AW: Rab1a regulates sorting of early endocytic vesicles. Am J Physiol Gastrointest Liver Physiol. 306:G412–G424. 2014.PubMed/NCBI View Article : Google Scholar
11	Charng WL, Yamamoto S, Jaiswal M, Bayat V, Xiong B, Zhang K, Sandoval H, David G, Gibbs S, Lu HC, et al: Drosophila tempura, a novel protein prenyltransferase α subunit, regulates notch signaling Via Rab1 and Rab11. PLoS Biol. 12(e1001777)2014.PubMed/NCBI View Article : Google Scholar
12	Wang C, Yoo Y, Fan H, Kim E, Guan KL and Guan JL: Regulation of Integrin β 1 recycling to lipid rafts by Rab1a to promote cell migration. J Biol Chem. 285:29398–29405. 2010.PubMed/NCBI View Article : Google Scholar
13	Tanaka M, Mun S, Harada A, Ohkawa Y, Inagaki A, Sano S, Takahashi K, Izumi Y, Osada-Oka M, Wanibuchi H, et al: Hsc70 contributes to cancer cell survival by preventing Rab1A degradation under stress conditions. PLoS One. 9(e96785)2014.PubMed/NCBI View Article : Google Scholar
14	Salem A, Almahmoudi R, Listyarifah D, Siponen M, Maaninka K, Al-Samadi A, Salo T and Eklund KK: Histamine H₄ receptor signalling in tongue cancer and its potential role in oral carcinogenesis-a short report. Cell Oncol (Dordr). 40:621–630. 2017.PubMed/NCBI View Article : Google Scholar
15	Coune PG, Bensadoun JC, Aebischer P and Schneider BL: Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease. J Parkinsons Dis. 1:373–387. 2011.PubMed/NCBI View Article : Google Scholar
16	Wu G, Yussman MG, Barrett TJ, Hahn HS, Osinska H, Hilliard GM, Wang X, Toyokawa T, Yatani A, Lynch RA, et al: Increased myocardial Rab GTPase expression: A consequence and cause of cardiomyopathy. Circ Res. 89:1130–1137. 2001.PubMed/NCBI View Article : Google Scholar
17	Shimada K, Uzawa K, Kato M, Endo Y, Shiiba M, Bukawa H, Yokoe H, Seki N and Tanzawa H: Aberrant expression of RAB1A in human tongue cancer. Br J Cancer. 92:1915–1921. 2005.PubMed/NCBI View Article : Google Scholar
18	Xu H, Qian M, Zhao B, Wu C, Maskey N, Song H, Li D, Song J, Hua K and Fang L: Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells. Oncol Rep. 37:1619–1626. 2017.PubMed/NCBI View Article : Google Scholar
19	Wang X, Liu F, Qin X, Huang T, Huang B, Zhang Y and Jiang B: Expression of Rab1A is upregulated in human lung cancer and associated with tumor size and T stage. Aging (Albany NY). 8:2790–2798. 2016.PubMed/NCBI View Article : Google Scholar
20	Xu BH, Li XX, Yang Y, Zhang MY, Rao HL, Wang HY and Zheng XF: Aberrant amino acid signaling promotes growth and metastasis of hepatocellular carcinomas through Rab1A-dependent activation of mTORC1 by Rab1A. Oncotarget. 6:20813–20828. 2015.PubMed/NCBI View Article : Google Scholar
21	Thomas JD, Zhang YJ, Wei YH, Cho JH, Morris LE, Wang HY and Zheng XFS: Rab1A Is an mTORC1 activator and a colorectal oncogene. Cancer Cell. 26:181–182. 2016.
22	Fan SJ, Snell C, Turley H, Li JL, McCormick R, Perera SM, Heublein S, Kazi S, Azad A, Wilson C, et al: PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer. Oncogene. 35:3004–3015. 2016.PubMed/NCBI View Article : Google Scholar
23	Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, et al: Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology. 66 (6 Suppl 1):S4–S34. 2005.PubMed/NCBI View Article : Google Scholar
24	Herr HW: Pathologic evaluation of radical cystectomy specimens. Cancer. 95:668–669. 2002.PubMed/NCBI View Article : Google Scholar
25	Hutagalung AH and Novick PJ: Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev. 91:119–149. 2011.PubMed/NCBI View Article : Google Scholar
26	Li Y, Wang HY and Zheng XF: Rab1 GTPases as oncogenes. Aging (Albany NY). 7:897–898. 2015.PubMed/NCBI View Article : Google Scholar
27	RAB1A Promotes Oncogenesis in Colorectal Cancer via mTORC1 Activation. Cancer Discovery. 4:1366. 2014.
28	Yang XZ, Wang R, Li XX, Yang Y, Wang HY and Zheng XS: Rab1A and Rab1B promote esophageal squamous cell carcinoma through activating mTORC1 signaling and inhibiting autophagy. AACR, 2016.
29	Zavadil J, Haley J, Kalluri R, Muthuswamy SK and Thompson E: Epithelial-mesenchymal transition. Cancer Res. 68:9574–9577. 2008.PubMed/NCBI View Article : Google Scholar
30	Seton-Rogers S: Epithelial-mesenchymal transition: Untangling EMT's functions. Nat Rev Cancer. 16(1)2016.PubMed/NCBI View Article : Google Scholar
31	Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 18:1926–1945. 2004.PubMed/NCBI View Article : Google Scholar
32	Becker MN, Wu KJ, Marlow LA, Kreinest PA, Vonroemeling CA, Copland JA and Williams CR: The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. Urol Oncol. 32:317–326. 2014.PubMed/NCBI View Article : Google Scholar